Summary
• Relmada Therapeutics, Inc. (RLMD) fell 7.1% in after-hours trading, bringing the price to $4.05.
• The company presented Phase 2 data for NDV-01 targeting non-muscle invasive bladder cancer and plans to advance to Phase 3 studies by 2026.
• Analysts continue to maintain a “Buy” rating on RLMD, highlighting a significant earnings surprise despite recent price volatility.
Relmada Therapeutics, Inc. (Nasdaq: RLMD) is down 7.1% in after-hours trading, moving to $4.05 compared to the previous close of $4.36. The decline occurred without a clear catalyst, reflecting routine market activity as investors reevaluate the stock.
Recent Developments in Clinical Trials
Recently, Relmada announced the presentation of its NDV-01 Phase 2 data at the Society for Urologic Oncology. The data highlighted results from the six-month follow-up of the ongoing trial targeting non-muscle invasive bladder cancer (NMIBC). The company intends to advance NDV-01 into Phase 3 studies for both high-risk and intermediate-risk NMIBC in the first half of 2026, which together account for approximately 80% of new NMIBC cases diagnosed annually in the United States.
SEC Filings and Corporate Updates
On December 15, 2025, Relmada filed an 8-K with the SEC, detailing updates pertinent to the company’s operations. The specific contents of the filing were not disclosed within the JSON data but are available for investor review. Notably, the filing took place today but does not appear to have influenced trading activity directly.
[chart type=’sec’ value=’RLMD’]
Market and Technical Picture
In terms of technical indicators, RLMD is currently showing an RSI of 61.73, suggesting the stock is moving towards an overbought condition. The average trading volume over the last 10 days was approximately 1.1 million shares, while the 3-month average volume stands at around 1.05 million shares. The stock’s 52-week performance has been highly volatile, with a yearly gain of 828.1%, though it has faced significant declines over the past three years.
[chart type=’price’ value=’RLMD’]
[chart type=’performance’ value=’RLMD’]
Analysts’ Perspective
Analysts maintain a “Buy” rating on RLMD, reflecting confidence in the company’s underlying potential despite the current price fluctuation. The last earnings report indicated a substantial earnings surprise of 660.1%, with the most recent actual loss of -$0.30 per share exceeding the estimate of -$0.04.
With the latest clarity from the company now reflected in trading, investors will be monitoring how the stock’s volume and momentum develop in the next session.